TABLE 1.
AbaR-type genomic island and antimicrobial resistance in non-baumannii Acinetobacter isolates harboring genomic islands
| Species | Isolate | Type | MIC (mg/liter) ofa: |
|||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| IMP | MEM | TET | CIP | RIF | AMK | CPM | CTR | CAZ | P/T | A/S | PB | COL | TIG | |||
| A. nosocomialis | H06-681 | Tn6022ΔtniD | 2 | 16 | >64 | >64 | 4 | >128 | >64 | >128 | >64 | >256/4 | 64/32 | 1 | 2 | 4 |
| H09-1045 | AbaR4 | >64 | >64 | 64 | 64 | 2 | 32 | 64< | 16 | 8 | >256/4 | 64/32 | 2 | 2 | 4 | |
| E09-34 | AbaR4 | >64 | >64 | >64 | 8 | 4 | 32 | 64< | 16 | 8 | >256/4 | >64/32 | 2 | 2 | 4 | |
| A. seiffertii | C044 | Tn6166 | 1 | 1 | >64 | >64 | 4 | >128 | 16 | >128 | >64 | 256/4 | 64/32 | 1 | 2 | 2 |
| C066 | Tn6022ΔtniD | 16 | 32 | 8 | >64 | 2 | 16 | >64 | >128 | >64 | >256/4 | 64/32 | 2 | 8 | 4 | |
IMP, imipenem; MEM, meropenem; TET, tetracycline; CIP, ciprofloxacin; RIF, rifampin; AMK, amikacin; CPM, cefepime; CTR, ceftriaxone; CAZ, ceftazidime; P/T, piperacillin-tazobactam; A/S, ampicillin-sulbactam; PB, polymyxin B; COL, colistin; TIG, tigecycline. MICs in bold indicate resistance. The breakpoints of resistance are from CLSI guidelines (11) for most antimicrobial resistance (resistance defined as ≥16 mg/liter for both imipenem and meropenem). The criteria recommended by the CLSI for staphylococci were applied for rifampin (resistance defined as ≥4 mg/liter), and the criteria of the U.S. Food and Drug Administration (FDA) for Enterobacteriaceae were used for tigecycline (resistance defined as ≥8 mg/liter) (18).